$99.20 +0.50 (%) Johnson & Johnson - NYSE

Oct. 20, 2014 | 04:00 PM

Partner Headlines

  1. Bill Frels Comments on Johnson & Johnson

    GuruFocus | Oct. 20, 2014 | 16:14PM EST
  2. Celgene's Crohn's Disease Drug Hits Its Marks

    IBD | Oct. 20, 2014 | 11:16AM EST
  3. What Have We Really Lost?

    GuruFocus | Oct. 20, 2014 | 10:10AM EST
  4. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga | Oct. 19, 2014 | 10:19AM EST
  5. Illumina Helps Make Gene Sequencing Affordable

    IBD | Oct. 17, 2014 | 18:48PM EST
  6. #PreMarket Primer: Thursday, October 16: This Year's Spending Season Could Be Muted

    Benzinga | Oct. 16, 2014 | 07:40AM EST
  7. The Key Drivers For Johnson & Johnson

    GuruFocus | Oct. 15, 2014 | 19:10PM EST
  8. Was Celgene's Crohn's Disease Drug Worth The Price?

    IBD | Oct. 15, 2014 | 17:39PM EST
  9. Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark'

    Benzinga | Oct. 15, 2014 | 16:42PM EST
  10. J&J raises outlook on Q3 beat

    IBD | Oct. 14, 2014 | 18:51PM EST
  11. Making Money With Charles Payne: 10/14/14

    FoxBusiness | Oct. 14, 2014 | 18:00PM EST
  12. Johnson & Johnson Conference Call Highlights

    Benzinga | Oct. 14, 2014 | 15:21PM EST
  13. Deutsche Bank Says Gilead Sciences Stock Reaction Is Overdone

    Benzinga | Oct. 14, 2014 | 13:59PM EST
  14. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD | Oct. 14, 2014 | 11:54AM EST
  15. Stocks Up, Whittle Early Gains; Skyworks Spikes On Guidance

    IBD | Oct. 14, 2014 | 10:42AM EST
  16. JPM Posts Mixed 3Q as Trading Rebounds

    FoxBusiness | Oct. 14, 2014 | 09:40AM EST
  17. J&J Worldwide Pharama Sales Growth YoY

    Benzinga | Oct. 14, 2014 | 07:55AM EST
  18. Earnings Scheduled For October 14, 2014

    Benzinga | Oct. 14, 2014 | 05:23AM EST
  19. Stocks To Watch For October 14, 2014

    Benzinga | Oct. 14, 2014 | 04:09AM EST
  20. Video: Intel Among Top 4 Earnings Reports Tuesday

    IBD | Oct. 13, 2014 | 16:26PM EST
  21. J&J's Alios BioPharma Reports Presented Positive Results of Anti-RSV Nucleoside Analog AL-8176

    Benzinga | Oct. 13, 2014 | 08:35AM EST
  22. Retail Sales Take the Stage, 3Q Earnings Rev Up

    FoxBusiness | Oct. 10, 2014 | 17:30PM EST
  23. Gilead's Hep C Combo Pill Harvoni Approved, Priced

    IBD | Oct. 10, 2014 | 15:13PM EST
  24. Making Money With Charles Payne: 10/08/14

    FoxBusiness | Oct. 9, 2014 | 18:00PM EST
  25. #PreMarket Primer: Wednesday, October 8: IMF Cuts Global Growth Prospects, Puts A Damper On Wall Street

    Benzinga | Oct. 8, 2014 | 08:19AM EST
  26. Health Care, Tech Names Offer Dividend Growth, Stability

    IBD | Oct. 3, 2014 | 18:29PM EST
  27. #PreMarket Primer: Friday, October 3: JP Morgan Suffers Largest Cyberattack Against A Financial Institution

    Benzinga | Oct. 3, 2014 | 07:03AM EST
  28. Will Gilead Sciences Score Healthy Gains For Investors?

    IBD | Oct. 2, 2014 | 13:03PM EST
  29. Sure Bets: Slow-Changing Industries for Long-Term Investors

    GuruFocus | Oct. 1, 2014 | 18:48PM EST
  30. Johnson & Johnson Falls On Bernstein Downgrade

    Benzinga | Oct. 1, 2014 | 15:09PM EST
  31. Stocks Sell Off On Europe Worries; Growth Names Slammed

    IBD | Oct. 1, 2014 | 15:04PM EST
  32. Why Mega-Cap Stocks Are Beating Broader Market

    YCharts | Oct. 1, 2014 | 12:02PM EST
  33. Benzinga's Top Downgrades

    Benzinga | Oct. 1, 2014 | 08:53AM EST
  34. Bernstein Downgrades Johnson & Johnson To Market Perform, Shares Drop

    Benzinga | Oct. 1, 2014 | 08:13AM EST
  35. J&J Moves Into Gilead's Turf

    IBD | Sep. 30, 2014 | 18:43PM EST
  36. Ireland Exporters Look To Thursday's ECB Policy Vote

    IBD | Sep. 30, 2014 | 18:24PM EST
  37. Stocks Move To Session Lows; Regeneron Rises On Drug Data

    IBD | Sep. 30, 2014 | 15:04PM EST
  38. Achillion Pharmaceuticals, Inc. Less Attractive Amid Johnson & Johnson/Alios BioPharma Deal

    Benzinga | Sep. 30, 2014 | 12:19PM EST
  39. J&J Buying Alios, Going Up Against Gilead

    IBD | Sep. 30, 2014 | 12:02PM EST
  40. #PreMarket Primer: Thursday, September 25: US Airstrikes Do Little To Stem ISIS Advances

    Benzinga | Sep. 25, 2014 | 07:27AM EST
  41. International Securities For A Diversified Income Portfolio

    GuruFocus | Sep. 23, 2014 | 13:36PM EST
  42. "A Unique Period of Time," Revisited

    GuruFocus | Sep. 22, 2014 | 10:48AM EST
  43. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD | Sep. 19, 2014 | 12:17PM EST
  44. Stocks Hitting 52-Week Highs

    Benzinga | Sep. 19, 2014 | 10:02AM EST
  45. New Active ETF for All Risk Environments

    Benzinga | Sep. 17, 2014 | 10:05AM EST
  46. 3 Companies Investing In Stem Cell Research

    Benzinga | Sep. 14, 2014 | 16:34PM EST
  47. Addressing Disengagement And Depression Lifts Workers

    IBD | Sep. 12, 2014 | 14:41PM EST
  48. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD | Sep. 11, 2014 | 17:41PM EST
  49. Steadier, Better: 35 Years Of Low-Volatility Stocks

    YCharts | Sep. 8, 2014 | 20:54PM EST
  50. Johnson & Johnson Metal Hip Might Lead To Poisoning, Facing 6,000+ Suits

    Benzinga | Sep. 4, 2014 | 17:16PM EST
Trading Center